feed icon

CVS Caremark is just so misunderstood

Posted on September 1, 2009 at 9:03 am

A week after Barron’s stated the case for the shares of CVS Caremark (Ticker: CVS), Fortune weighs in on the topic. Even though the stock has beaten the S&P by 16 points this year, it trails its peers.

The market questions whether a drugstore chain, which has expertise in retail sales, can run a PBM, which negotiates on behalf of employers and insurance plans to purchase drugs from pharmaceutical companies. As a result, CVS’s price/earnings ratio for the next 12 months is 13, while Walgreen’s is 15 and Medco’s is 20. That makes CVS, which is poised for strong growth, a bargain - no matter how the health-reform battle plays out.

Comments

Leave a Reply




Recent Comments

The Conglomerate